Lilly/BI 'biosimilar Lantus' filed in Europe
This article was originally published in Scrip
Executive Summary
Eli Lilly and and Boehringer Ingelheim have had their marketing authorization application (MAA) for the biosimilar LY2963016, a basal (long-acting) insulin analog for the treatment of type 1 and type 2 diabetes, accepted for review by the European Medicines Agency. LY2963016 is a new insulin glargine product and was filed through the EMA's biosimilar pathway.